Today: 21 July 2026
Figma stock price (FIG) ends Friday higher into a holiday week as earnings loom
15 February 2026
2 mins read

Figma stock price (FIG) ends Friday higher into a holiday week as earnings loom

New York, Feb 14, 2026, 19:31 ET — The closing bell has sounded.

  • Figma wrapped up Friday at $22.53, notching a 2.3% gain on the day. Roughly 9.3 million shares changed hands.
  • U.S. equity markets will be shuttered Monday for Washington’s Birthday, leaving traders with a shortened week ahead.
  • Figma plans to release its results after the bell on Feb. 18, with a conference call set for 5 p.m. ET.

Figma closed out Friday at $22.53, a 2.3% gain, with the stock swinging from $22.17 to $23.37 during the session. It’s still sitting roughly 84% below its 52-week peak of $142.92, though shares have climbed about 14% off the $19.85 low.

Next week’s setup isn’t roomy. With U.S. markets closed Monday for Washington’s Birthday, investors lose a session to adjust positions before major tech and software earnings arrive.

Figma faces a numbers check soon. The company plans to post its fourth-quarter and full-year 2025 results after the U.S. market wraps on Wednesday, Feb. 18, followed by a Q&A session on a conference call.

Product updates didn’t take a break for the weekend. Figma’s release notes this week highlighted new local data hosting now available in Australia and India, a move geared toward regional data residency and compliance demands. The company also outlined a tweak to tab navigation on its desktop app, targeting busy workspaces.

Filings made share supply visible once again. According to a Form 4, General Counsel and Secretary Brendan Mulligan sold 5,227 shares at $25 each on Feb. 10, leaving him with 850,489 shares after the move. The document noted this sale came via a Rule 10b5-1 plan—a pre-set schedule for trades.

Chief Technology Officer Kris Rasmussen offloaded 205,438 shares at an average price of $25.0127, according to a separate Form 4. The sale was executed under a 10b5-1 plan set up in August.

Back in November, Figma posted a 38% jump in third-quarter revenue, reaching $274.2 million, and bumped up its outlook for the year. The company projected fourth-quarter sales somewhere between $292 million and $294 million. CEO Dylan Field described it as “the best quarter in Figma’s history.” CFO Praveer Melwani pointed out Figma still has “the flexibility to keep investing” as it chases more growth. Figma Investor Relations

The spending spree is taking a toll. “Near-term margin compression,” is how Melwani described it to Reuters, pointing to higher costs from rolling out new products. He expects that squeeze to let up once more tools start generating revenue. Reuters highlighted Figma’s push into AI—Figma Make, plus a ChatGPT tie-in—as key to attracting more users. Reuters

Figma remains in a packed field of design software, with Adobe continuing to loom large—especially after regulators blocked Adobe’s $20 billion bid for Figma last year. The competition isn’t letting up.

The stock has already fallen off last year’s highs, so investors aren’t likely to wait around for another weak outlook. If growth slows more than expected—or if spending keeps cutting into profits longer than people thought—the latest rally could easily unravel.

All eyes now turn to Feb. 18, when Figma is set to release its Q4 and full-year numbers after the bell. The company’s guidance, along with the 5 p.m. ET call, will likely shape sentiment for FIG once trading picks up again post-holiday.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors. Follow Khadija Saeed on Google News.

Stock Market Today

  • Cadiz, ArriVent BioPharma, Acco Brands join Zacks Strong Sell list for July 21st
    July 21, 2026, 6:12 AM EDT. Cadiz (CDZI), ArriVent BioPharma (AVBP), and Acco Brands (ACCO) were added to the Zacks Rank #5 (Strong Sell) List. Cadiz's earnings estimate tumbled 40%, while ArriVent BioPharma slipped 7.3% and Acco Brands dropped 5.1% in consensus earnings over the past 60 days. These moves mark a significant slide in expected earnings for July 21st.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz
Previous Story

Stock Market Today 12.02.2026

Uber stock: Tuesday test looms after Uber Eats targets $1 billion boost in Europe
Next Story

Uber stock: Tuesday test looms after Uber Eats targets $1 billion boost in Europe

Go toTop